AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24338466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 7.5 mg Levobupivacaine 0.25% plus sufentanil 2.5 μg (Group L0.25)
Number of subjects: 70
Study 24338466 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 7.5 mg Levobupivacaine 0.50% plus sufentanil 2.5 μg (GroupControl)
Number of subjects: 70
Study 21289522 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-101 (40 mg b.i.d. × 3 days) plus docetaxel (75 mg/m on day 1) every 21 days
Number of subjects: 106
Study 21289522 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (75 mg/m on day 1) every 21 days
Number of subjects: 106
Study 19649687 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (MG)
Number of subjects: 135
Study 19649687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (OG)
Number of subjects: 135
Study 19649687 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 135
Study 17372130 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg
Number of subjects: 90
Study 17372130 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg
Number of subjects: 90
Study 15035723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) 20 mg/kg daily for 4 weeks
Number of subjects: 60
Study 15035723 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AMB) 1 mg/kg daily for 20 days
Number of subjects: 60
Study 11511481 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospital transfer
Number of subjects: 0
Study 11511481 — intervention group
Group type: COMPARATOR
Intervention: Remaining in a district general hospital
Number of subjects: 0
Study 9663178 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg
Number of subjects: 9
Study 9663178 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 9
Study 9663178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8154037 — intervention group
Group type: EXPERIMENTAL
Intervention: DILT (60 mg b.i.d.)
Number of subjects: 3
Study 8154037 — intervention group
Group type: EXPERIMENTAL
Intervention: KETO (200 mg/day)
Number of subjects: 3
Study 8154037 — intervention group
Group type: COMPARATOR
Intervention: Control (TRIPLE with CsA 8 mg/kg/day)
Number of subjects: 3
Study 8154037 — intervention group
Group type: EXPERIMENTAL
Intervention: KETO
Number of subjects: 3
Study 3292185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (3 g as a single dose)
Number of subjects: 12
Study 3292185 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg as a single dose)
Number of subjects: 12
Study 3292185 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 g plus another 0.5 g after six hours)
Number of subjects: 12
Study 30720697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic splenectomy (HALS)
Number of subjects: 91
Study 30720697 — intervention group
Group type: COMPARATOR
Intervention: Complete laparoscopic splenectomy (LS)
Number of subjects: 91
Study 28283600 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia (blood glucose ≥7.8 mmol/L)
Number of subjects: 1676
Study 28283600 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia in patients with diabetes mellitus (n = 418)
Number of subjects: 1676
Study 26585940 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammalian cell-derived quadrivalent influenza vaccine (QIVc)
Number of subjects: 2333
Study 26585940 — intervention group
Group type: COMPARATOR
Intervention: Trivalent influenza vaccines (TIV1c/TIV2c)
Number of subjects: 2333
Study 24251363 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of warfarin
Number of subjects: 455
Study 24251363 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of warfarin (control)
Number of subjects: 455
Study 21236548 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED)
Number of subjects: 2
Study 21236548 — intervention group
Group type: COMPARATOR
Intervention: Vibration measurement on the floor of the helicopter
Number of subjects: 2
Study 18545884 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure haemorrhoidectomy
Number of subjects: 44
Study 18545884 — intervention group
Group type: COMPARATOR
Intervention: Diathermy haemorrhoidectomy
Number of subjects: 44
Study 21334545 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented soft tissue mobilization (ASTM) twice a week for 5 weeks
Number of subjects: 27
Study 21334545 — intervention group
Group type: COMPARATOR
Intervention: Advice on the natural evolution of lateral epicondylitis, computer ergonomics, and stretching exercises (Control)
Number of subjects: 27
Study 16162880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive management
Number of subjects: 1200
Study 16162880 — intervention group
Group type: COMPARATOR
Intervention: Selectively invasive management
Number of subjects: 1200
Study 11844507 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned community postnatal care led by midwives
Number of subjects: 2064
Study 11844507 — intervention group
Group type: COMPARATOR
Intervention: Control group care (standard care)
Number of subjects: 2064
Study 9828756 — intervention group
Group type: EXPERIMENTAL
Intervention: HF/SW snacks
Number of subjects: 36
Study 9828756 — intervention group
Group type: EXPERIMENTAL
Intervention: LF/NSW snacks
Number of subjects: 36
Study 9828756 — intervention group
Group type: EXPERIMENTAL
Intervention: HF snacks
Number of subjects: 36
Study 9828756 — intervention group
Group type: EXPERIMENTAL
Intervention: LF snacks
Number of subjects: 36
Study 9828756 — intervention group
Group type: COMPARATOR
Intervention: General snack consumption
Number of subjects: 36
Study 8569932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloriset IgG at a cut-off value of 500 U/l
Number of subjects: 154
Study 8569932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloriset IgG at a cut-off value of 350 U/l (excluding patients aged above 70 years)
Number of subjects: 154
Study 8569932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloriset IgG in patients under the age of 45 years
Number of subjects: 154
Study 2548135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate
Number of subjects: 95
Study 2548135 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogens + 5 mg medroxyprogesterone acetate
Number of subjects: 95
Study 2548135 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogens + placebo
Number of subjects: 95
Study 2548135 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg conjugated equine estrogens + placebo
Number of subjects: 95
Study 321823 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 500
Study 321823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 29879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction_CS+
Number of subjects: 0
Study 29879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction_Singular
Number of subjects: 0
Study 29879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction_Variety
Number of subjects: 0
Study 27160404 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin‐mediated dilation (NMD)
Number of subjects: 0
Study 27160404 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow‐mediated dilation (FMD)
Number of subjects: 0
Study 27160404 — intervention group
Group type: COMPARATOR
Intervention: Other vascular function tests (VFTs)
Number of subjects: 0
Study 25023444 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ganglioside complex milk lipid (CML)
Number of subjects: 450
Study 25023444 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 450
Study 22642526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 41
Study 20689094 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 19
Study 20689094 — intervention group
Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 19
Study 20689094 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 19
Study 18182665 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone (D3P)
Number of subjects: 1006
Study 18182665 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel plus prednisone (D1P)
Number of subjects: 1006
Study 18182665 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (MP)
Number of subjects: 1006
Study 15795146 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA plus continuous background infusion (4 mL/h plus an hourly maximum of three 4‐mL boluses on demand, lock‐out time 20 min)
Number of subjects: 66
Study 15795146 — intervention group
Group type: COMPARATOR
Intervention: Demand-only PCEA (hourly maximum of four 4‐mL boluses, lock‐out time 15 min)
Number of subjects: 66
Study 15795146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (PCEA plus continuous background infusion and demand-only PCEA)
Number of subjects: 66
Study 15795146 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA plus continuous background infusion
Number of subjects: 66
Study 15795146 — intervention group
Group type: COMPARATOR
Intervention: Demand-only PCEA
Number of subjects: 66
Study 14500274 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound measurement of speed of sound (SOS) at the tibia using SoundScan 2000 device
Number of subjects: 1596
Study 14500274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for osteoporosis based on SOS<or=3733 m s(‐1) and T‐score<or=‐3.8
Number of subjects: 1596
Study 14500274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic criteria based on SOS<or=3800 m s(‐1) and T‐score<or=‐2.0
Number of subjects: 1596
Study 14500274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SOS between pre-menopausal and post-menopausal women aged 40-59 years
Number of subjects: 1596
Study 14500274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of osteoporosis in pre-menopausal vs post-menopausal women aged 40-59 years
Number of subjects: 1596
Study 10396715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 28
Study 10396715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 28
Study 10396715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 28
Study 10396715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9345495 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized and validated cross-lingual experimental task
Number of subjects: 77
Study 9345495 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 77
Study 1684465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate
Number of subjects: 0
Study 1684465 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐anoic acid
Number of subjects: 0
Study 1684465 — intervention group
Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 0
Study 7006557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 44
Study 7006557 — intervention group
Group type: COMPARATOR
Intervention: Imipramine hydrochloride (pharmacotherapy)
Number of subjects: 44
Study 31519673 — intervention group
Group type: EXPERIMENTAL
Intervention: Journeying through Dementia (JtD) intervention
Number of subjects: 486
Study 31519673 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 486
Study 28301098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg AER (under fasting conditions)
Number of subjects: 30
Study 28301098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg AER (under fed conditions)
Number of subjects: 30
Study 28301098 — intervention group
Group type: COMPARATOR
Intervention: 2 mg CARP
Number of subjects: 30
Study 28301098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg AER
Number of subjects: 30
Study 26875003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 56
Study 26875003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 56
Study 25400472 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative restricted fluid therapy (R, n = 96)
Number of subjects: 185
Study 25400472 — intervention group
Group type: COMPARATOR
Intervention: Perioperative standard fluid therapy (S, n = 89)
Number of subjects: 185
Study 22572687 — intervention group
Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Number of subjects: 83
Study 22572687 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy 6 weeks later
Number of subjects: 83
Study 20482508 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (anxiolytic, 5-HT(1A) partial agonist)
Number of subjects: 0
Study 20482508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (serotonergic drug)
Number of subjects: 0
Study 20482508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (5-HT(3) antagonist)
Number of subjects: 0
Study 20482508 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (Selective serotonin reuptake inhibitors)
Number of subjects: 0
Study 20482508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 18397680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0
Study 18397680 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 16208053 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath holding children
Number of subjects: 50
Study 11879258 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg twice daily on days 2-6)
Number of subjects: 50
Study 11879258 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (500 mg once daily on days 2-4)
Number of subjects: 50
Study 12489923 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (8-week program, 6 days/week)
Number of subjects: 19
Study 12489923 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (T)
Number of subjects: 19
Study 10689656 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial motivationally based, four-session outpatient treatment; n = 67
Number of subjects: 136
Study 10689656 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental intervention for nonresponders; n = 33
Number of subjects: 136
Study 10689656 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders without supplemental intervention; n = 36
Number of subjects: 136
Study 7510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-bleomycin-5-fluorouracil (PBF) in 31 patients
Number of subjects: 64
Study 7510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-5-fluorouracil (PF) in 33 patients
Number of subjects: 64
Study 7510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-5-fluorouracil (PF)
Number of subjects: 64
Study 7510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-bleomycin-5-fluorouracil (PBF)
Number of subjects: 64
Study 7510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival with laryngeal preservation
Number of subjects: 64
Study 7510276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall 2-year survival rates
Number of subjects: 64
Study 2518847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesasal tablets, 2 x 250 mg, fasting
Number of subjects: 12
Study 2518847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesasal tablets, 2 x 250 mg, fed
Number of subjects: 12
Study 2518847 — intervention group
Group type: COMPARATOR
Intervention: Salazopyrin tablets, 3 x 500 mg (corresponding to 576 mg 5‐ASA), fasting
Number of subjects: 12
Study 2518847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesasal suppository, 1 x 500 mg, fasting
Number of subjects: 12
Study 568493 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 dB white noise stimulus
Number of subjects: 48
Study 568493 — intervention group
Group type: COMPARATOR
Intervention: 60 dB white noise stimulus
Number of subjects: 48
Study 568493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-paced mental arithmetic task
Number of subjects: 48
Study 568493 — intervention group
Group type: COMPARATOR
Intervention: Slow-paced mental arithmetic task
Number of subjects: 48
Study 31495292 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg once then 850 mg twice daily for two weeks
Number of subjects: 24
Study 31495292 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 24
Study 31495292 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (double dose 1700 mg)
Number of subjects: 24
Study 31495292 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (single dose 850 mg)
Number of subjects: 24
Study 31495292 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (both doses)
Number of subjects: 24
Study 31229621 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone health coaching to help select and enroll in WMPs
Number of subjects: 168
Study 31229621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health coaching)
Number of subjects: 168
Study 31229621 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone health coaching (≥4 calls)
Number of subjects: 168
Study 31229621 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone health coaching
Number of subjects: 168
Study 28345778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal pressure biofeedback (P‐BF) assisted pelvic floor muscle (PFM) exercises
Number of subjects: 53
Study 28345778 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal electromyographic biofeedback (EMG‐BF) assisted pelvic floor muscle (PFM) exercises
Number of subjects: 53
Study 28345778 — intervention group
Group type: COMPARATOR
Intervention: PFM home exercise program alone
Number of subjects: 53
Study 25261154 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback about performance on a 10-meter walk (speed only)
Number of subjects: 135
Study 25261154 — intervention group
Group type: COMPARATOR
Intervention: Walking speed feedback plus a review of walking activity recorded by the sensors (augmented)
Number of subjects: 135
Study 23829147 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured peer assessment based on Calibrated Peer Review
Number of subjects: 48
Study 23829147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no facilitative resources)
Number of subjects: 48
Study 21291446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring (treatment group)
Number of subjects: 1139
Study 21291446 — intervention group
Group type: COMPARATOR
Intervention: No mentoring (control group)
Number of subjects: 1139
Study 19836995 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at varying intensities applied to the posterior fossa (PF) with ISIs of 5 or 7 ms
Number of subjects: 11
Study 19836995 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at varying intensities applied to the posterior fossa (PF) with ISI of 3 ms
Number of subjects: 11
Study 19836995 — intervention group
Group type: EXPERIMENTAL
Intervention: PF stimuli alone
Number of subjects: 11
Study 17082240 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi (trandolapril 2 mg/d)
Number of subjects: 1204
Study 17082240 — intervention group
Group type: EXPERIMENTAL
Intervention: ndCCB (verapamil SR 240 mg/d)
Number of subjects: 1204
Study 17082240 — intervention group
Group type: EXPERIMENTAL
Intervention: Veratran (trandolapril 2 mg/d plus verapamil SR 180 mg/d)
Number of subjects: 1204
Study 17082240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204
Study 15021839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24
Study 15021839 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 24
Study 15021839 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 24
Study 11704899 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of Emotional Intelligence (TEI)
Number of subjects: 41
Study 11704899 — intervention group
Group type: COMPARATOR
Intervention: Integrated Psychological Therapy Program (IPT)
Number of subjects: 41
Study 9265917 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 817
Study 9265917 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 817
Study 7924757 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (repeated doses)
Number of subjects: 10
Study 7924757 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (third dose)
Number of subjects: 10
Study 7924757 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (all doses)
Number of subjects: 10
Study 2891365 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg
Number of subjects: 50
Study 2891365 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 5 mg
Number of subjects: 50
Study 2891365 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery (no intervention)
Number of subjects: 50
Study 30081211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-training in apnea and physical activity (CT; n = 10)
Number of subjects: 29
Study 30081211 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea training only (AT; n = 10)
Number of subjects: 29
Study 30081211 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 9)
Number of subjects: 29
Study 30081211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-training in apnea and physical activity (CT)
Number of subjects: 29
Study 29409488 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTechnetium‐labelled monodisperse salbutamol (1.5 μm)
Number of subjects: 9
Study 29409488 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTechnetium‐labelled monodisperse salbutamol (6 μm)
Number of subjects: 9
Study 29409488 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydisperse nebulisation of salbutamol
Number of subjects: 9
Study 29409488 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydisperse pMDI inhalation of salbutamol (400 μg)
Number of subjects: 9
Study 26712188 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy with fiberoptic bronchoscopy (Group B)
Number of subjects: 60